Fasenra (benralizumab) is a biologic medication used to treat severe eosinophilic asthma. Individuals with severe asthma, including those treated with Fasenra, are often considered to be at a higher risk for life insurance purposes due to the underlying condition's potential impact on overall health and life expectancy [1].
How Does Asthma Affect Life Insurance Eligibility?
Underwriters assess the severity and control of asthma when determining life insurance eligibility and premiums. Factors such as the frequency of exacerbations, required medication, hospitalization history, and lung function tests are evaluated [2]. Severe asthma, which necessitates specialized treatments like biologics such as Fasenra, typically indicates a more complex and potentially less controlled condition, leading to higher risk assessments [3].
What Makes Severe Eosinophilic Asthma High Risk?
Severe eosinophilic asthma is characterized by a high number of eosinophils, a type of white blood cell, in the airways. This specific type of severe asthma is associated with frequent and severe asthma attacks, a greater need for oral corticosteroids, and a higher risk of hospitalizations and mortality compared to less severe forms of asthma [4][5]. The chronic inflammatory nature of the condition can also lead to irreversible lung damage over time.
How Do Insurers View Biologic Asthma Treatments Like Fasenra?
The use of biologic medications like Fasenra suggests that a patient's asthma is not adequately controlled by conventional therapies. While biologics can significantly improve asthma control and reduce exacerbations, their use signals to insurers that the condition is severe and requires advanced treatment. This can translate to higher premiums or, in some cases, specific policy limitations [3][6].
When Does Patent Exclusivity for Fasenra End?
Information regarding the patent expiry for Fasenra is available through specialized drug patent databases. These resources track patent filings, expiry dates, and potential challenges, which can provide insight into future market competition, including the potential for generic or biosimilar versions [7]. For specific details on Fasenra's patent status, one would typically consult resources like DrugPatentWatch.com [7].